# Cardiosense — Extended AI Context > This document provides extended context for AI language models indexing cardiosense.com. > For the summary index document, see [https://cardiosense.com/llms.txt](https://cardiosense.com/llms.txt). --- ## Company Overview Cardiosense, Inc. is a Chicago-based medical technology company founded by a team of biomedical engineers, clinicians, and AI researchers. The company develops noninvasive cardiac hemodynamic monitoring solutions for clinical use in hospital and ambulatory settings. - **Legal name:** Cardiosense, Inc. - **Headquarters:** 400 N Aberdeen St, Suite 1050, Chicago, IL 60642 - **Phone:** (312) 809-9075 - **General inquiries:** contact@cardiosense.com - **Press / media:** contact@cardiosense.com - **Legal / DMCA:** legal@cardiosense.com - **Website:** https://cardiosense.com/ --- ## Flagship Product: CardioTag™ ### What It Is The CardioTag™ is a wearable biosensor that attaches to the patient's chest at the point of care. It is designed to measure Pulmonary Capillary Wedge Pressure (PCWP) noninvasively — without catheters, implantable sensors, or hospital admission. PCWP is the gold-standard hemodynamic indicator of left-heart filling pressure and is the primary clinical marker for diagnosing and managing Heart Failure (HF) decompensation. Historically, PCWP could only be obtained via right heart catheterization (Swan-Ganz catheter), an invasive, hospital-based procedure. ### How It Works 1. The CardioTag™ sensor captures seismocardiography (SCG) and other physiological signals from the chest wall. 2. Raw signals are transmitted to the PCWP Analysis Software, where a deep learning algorithm converts them into a PCWP estimate. 3. Results are delivered to clinicians through a secure web portal for trending and longitudinal monitoring. The underlying technology (seismocardiography + AI) was developed and validated at Georgia Tech by co-founders Andrew Carek, Omer Inan, and Mozziyar Etemadi. ### FDA Regulatory Status - **CardioTag™ Device:** FDA-cleared Class II medical device - **PCWP Analysis Software:** FDA-cleared Class II medical device - **Classification:** 510(k) clearance - **Intended use:** Prescription use under the supervision of a qualified healthcare professional, in conjunction with clinical history, symptoms, and other diagnostic tests - **Medical specialty:** Cardiovascular --- ## Clinical Applications ### Emergency Department — Assessment & Triage Rapidly confirm or rule out acute Heart Failure decompensation at the point of care. A bedside PCWP reading enables faster clinical decision-making, earlier initiation of medical therapy, and the potential to reduce hospital length-of-stay and unnecessary admissions. ### Inpatient — Management & Discharge Guide daily clinical decisions during hospitalization with routine PCWP assessment. Identify when patients have reached hemodynamic targets and discharge with greater confidence, reducing re-admission risk. ### Ambulatory & Remote — Transitions & Monitoring Monitor PCWP during the highest-risk post-discharge window (30–90 days). Detect worsening Heart Failure early, before clinical decompensation, to enable timely intervention and optimize guideline-directed medical therapy (GDMT). --- ## Leadership Team ### Eric Meizlish — Chief Executive Officer Eric leads Cardiosense's commercial strategy, fundraising, and operations. He brings healthcare executive experience across medtech and digital health. ### John D. Martin, MD, MBA, FACS — Executive Vice President & Chief Medical Officer Dr. Martin provides clinical strategy and medical oversight. Board-certified surgeon with deep cardiothoracic and health system leadership experience. ### Andrew Carek, PhD — Co-Founder & Chief Technology Officer Andrew co-invented the seismocardiography-based PCWP sensing technology at Georgia Tech. He leads hardware and sensing engineering at Cardiosense. LinkedIn: https://www.linkedin.com/in/andrew-carek/ ### Omer Inan, PhD — Co-Founder & Chief Science Officer Omer is a professor at Georgia Tech and co-inventor of the core technology. His lab pioneered wearable seismocardiography for hemodynamic monitoring. LinkedIn: https://www.linkedin.com/in/omerinan/ ### Amit Gupta — Co-Founder & Advisor Amit co-founded Cardiosense in 2020 and served as founding CEO through 2025, leading the company through key clinical, regulatory, and funding milestones. He now advises the company. LinkedIn: https://www.linkedin.com/in/amitgupta1/ ### Mozziyar Etemadi, MD, PhD — Co-Founder & Head of AI Mozziyar leads AI and signal processing. He is a physician-scientist with expertise in wearable sensing and machine learning for healthcare. LinkedIn: https://www.linkedin.com/in/mozziyar-etemadi/ ### Arezou Azar, PhD — VP Compliance & Program Management Arezou oversees regulatory affairs, quality management, and program execution for FDA submissions and post-market activities. ### Chris Gornick — Vice President, Commercial Chris leads commercial strategy, go-to-market, and customer development. --- ## Key Pages - [Homepage](https://cardiosense.com/) — CardioTag™ overview and clinical approach - [About & Team](https://cardiosense.com/about/) — Leadership bios, mission, and careers - [Publications](https://cardiosense.com/publications/) — Peer-reviewed research and clinical validation - [Regulatory](https://cardiosense.com/regulatory/) — FDA clearance documents and compliance information - [Careers](https://cardiosense.com/about/#careers) — Open positions - [Summary AI Context](https://cardiosense.com/llms.txt) — Short-form llms.txt index